1006 related articles for article (PubMed ID: 30745366)
41. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
42.
Godfrey J; Tumuluru S; Bao R; Leukam M; Venkataraman G; Phillip J; Fitzpatrick C; McElherne J; MacNabb BW; Orlowski R; Smith SM; Kline J
Blood; 2019 May; 133(21):2279-2290. PubMed ID: 30910787
[TBL] [Abstract][Full Text] [Related]
43. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
[TBL] [Abstract][Full Text] [Related]
44. IQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL.
Tang T; Wang J; Zhang L; Cheng Y; Saleh L; Gu Y; Zhang H
BMC Cancer; 2021 May; 21(1):603. PubMed ID: 34034707
[TBL] [Abstract][Full Text] [Related]
45. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
[TBL] [Abstract][Full Text] [Related]
46. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
47. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
Antonia SJ; Vansteenkiste JF; Moon E
Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
[TBL] [Abstract][Full Text] [Related]
48. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
49. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
[TBL] [Abstract][Full Text] [Related]
50. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
[TBL] [Abstract][Full Text] [Related]
51. Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
Ishikawa E; Nakamura M; Shimada K; Tanaka T; Satou A; Kohno K; Sakakibara A; Furukawa K; Yamamura T; Miyahara R; Nakamura S; Kato S; Fujishiro M
J Gastroenterol; 2020 Jan; 55(1):39-50. PubMed ID: 31493237
[TBL] [Abstract][Full Text] [Related]
52. Implication of immune cell signature of tumor microenvironment in diffuse large B-cell lymphoma.
Yu H; Fu D; Xu PP; Cheng S; Wang L; Zhang YZ; Zhao WL
Hematol Oncol; 2021 Dec; 39(5):616-624. PubMed ID: 34331367
[TBL] [Abstract][Full Text] [Related]
53. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
54. Prognostic Impact of the Immunoscore Based on Whole-Slide Image Analysis of CD3+ Tumor-Infiltrating Lymphocytes in Diffuse Large B-Cell Lymphoma.
Han B; Yim J; Lim S; Na S; Lee C; Kim TM; Paik JH; Kim S; Jeon YK
Mod Pathol; 2023 Sep; 36(9):100224. PubMed ID: 37257823
[TBL] [Abstract][Full Text] [Related]
55. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
56. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
57. A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL.
Miyawaki K; Kato K; Sugio T; Sasaki K; Miyoshi H; Semba Y; Kikushige Y; Mori Y; Kunisaki Y; Iwasaki H; Miyamoto T; Kuo FC; Aster JC; Ohshima K; Maeda T; Akashi K
Blood Adv; 2022 Apr; 6(7):2388-2402. PubMed ID: 34638128
[TBL] [Abstract][Full Text] [Related]
58. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
59. Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome.
Augé H; Notarantonio AB; Morizot R; Quinquenel A; Fornecker LM; Hergalant S; Feugier P; Broséus J
Front Immunol; 2020; 11():594841. PubMed ID: 33381116
[TBL] [Abstract][Full Text] [Related]
60. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]